Kara N. Maxwell

Oct 10, 2024 | digitalcommons.library.tmc.edu | Kara N. Maxwell |Vishal Patel |Kevin T Nead |Shana Merrill

Home > UTHealth > GSBS > Student and Faculty Publications > 1767 Student and Faculty Publications Clinical Genetics Humans, BRCA2 Protein, Fanconi Anemia, Neoplasms, Siblings, Young Adult DOWNLOADS Included in Bioinformatics Commons, Biomedical Informatics Commons, Medical Sciences Commons, Oncology Commons COinS...

Aug 9, 2024 | onclive.com | Kara N. Maxwell

Kara N. Maxwell, MD, PhD, assistant professor of medicine (hematology-oncology), Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, discusses the risk of developing cancer for males carrying germline BRCA1 and BRCA2 mutations.

Jun 14, 2024 | healio.com | Jennifer Byrne |Mindy Valcarcel |Kara N. Maxwell

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Only a small percentage of men recommended to undergo genetic testing due to personal or family history of cancer actually received it, according to findings published in Journal of the National Comprehensive Cancer Network.

May 23, 2024 | onclive.com | Kara N. Maxwell

Kara N. Maxwell, MD, PhD, assistant professor, medicine (hematology-oncology), Department of Medicine, Perelman School of Medicine, University of Pennsylvania, discusses key takeaways from a real-world investigation of germline mutation rates in patients with metastatic prostate cancer. A recent study focusing on patients with metastatic prostate cancer has revealed that the real-world prevalence of DNA repair pathogenic germline variants is lower than the rate reported in prior literature.

May 20, 2024 | onclive.com | Kara N. Maxwell

Kara N. Maxwell, MD, PhD, assistant professor, medicine (hematology-oncology), Department of Medicine, Perelman School of Medicine, University of Pennsylvania, discusses the accessibility of genetic testing in the community setting for patients with metastatic prostate cancer. In a study of patients with metastatic prostate cancer, researchers found that the real-world rates of DNA repair pathogenic germline variants were lower than previously reported.